Ferroptosis is an iron-dependent, lipid-peroxidation-driven form of regulated cell death that contributes to neuronal loss in Alzheimer's disease. First described in 2012, ferroptosis represents a unique cell death mechanism distinct from apoptosis, necrosis, and autophagy[@dixon2012][Dixon SJ 2012, Ferroptosis: an iron-dependent form of nonapoptotic cell death](https://pubmed.ncbi.nlm.nih.gov/32984395/). The pathway represents a critical intersection of iron dysregulation, lipid metabolism, and oxidative stress in neurodegenerative disease pathogenesis. Unlike other forms of cell death, ferroptosis is specifically characterized by the iron-catalyzed accumulation of lipid peroxides, making it particularly relevant to diseases where iron homeostasis is disturbed and membrane lipids are abundant[Stockwell BR 2022, Ferroptosis: a regulated necrosis](https://doi.org/10.1016/j.cell.2022.01.010).
Ferroptosis is an iron-dependent, lipid-peroxidation-driven form of regulated cell death that contributes to neuronal loss in Alzheimer's disease. First described in 2012, ferroptosis represents a unique cell death mechanism distinct from apoptosis, necrosis, and autophagy[@dixon2012][Dixon SJ 2012, Ferroptosis: an iron-dependent form of nonapoptotic cell death](https://pubmed.ncbi.nlm.nih.gov/32984395/). The pathway represents a critical intersection of iron dysregulation, lipid metabolism, and oxidative stress in neurodegenerative disease pathogenesis. Unlike other forms of cell death, ferroptosis is specifically characterized by the iron-catalyzed accumulation of lipid peroxides, making it particularly relevant to diseases where iron homeostasis is disturbed and membrane lipids are abundant[Stockwell BR 2022, Ferroptosis: a regulated necrosis](https://doi.org/10.1016/j.cell.2022.01.010).
The brain is particularly vulnerable to iron dysregulation due to several factors: high oxygen consumption rates generating reactive oxygen species, high lipid content rich in polyunsaturated fatty acids (PUFAs), and limited regenerative capacity of neurons. In Alzheimer's disease, brain iron accumulation occurs in multiple regions, with particularly notable increases in the substantia nigra, hippocampus, and cortical areas[@masaldan2023][Masaldan S 2023, Iron accumulation in aging and neurodegeneration](https://doi.org/10.1038/s41582-023-00767-5). This iron overload results from a combination of increased import, decreased export, and release from storage proteins during cellular stress.
The mechanisms driving iron accumulation in AD are multifactorial. Transferrin, the primary iron transport protein in the brain, becomes saturated, leading to the appearance of non-transferrin-bound iron (NTBI) that can enter cells through alternative pathways[Raz L 2015, Iron accumulation in the brain with aging](https://pubmed.ncbi.nlm.nih.gov/21822208/). The divalent metal transporter 1 (DMT1) facilitates iron import, and its expression is upregulated in AD brain tissue. Ferritin, the iron storage protein, increases in AD but appears insufficient to safely sequester the excess iron, leading to a labile iron pool that can catalyze free radical formation.
Ferritinophagy, the selective autophagic degradation of ferritin, is a key pathway releasing free iron in neurons. The cargo receptor NCOA4 (Nuclear Receptor Coactivator 4) delivers ferritin to lysosomes for degradation, releasing iron that can then participate in Fenton chemistry[@cai2023][Cai Z 2023, NCOA4-mediated ferritinophagy in neurodegenerative diseases](https://pubmed.ncbi.nlm.nih.gov/36789123/). In AD, ferritinophagy appears to be dysregulated, contributing to iron-mediated toxicity.
Lipid peroxidation represents the hallmark biochemical feature of ferroptosis. The process begins with the generation of lipid hydroperoxides (LOOH) from polyunsaturated fatty acids (PUFAs) in cellular membranes. PUFAs, particularly arachidonic acid and adrenic acid, are abundant in neuronal membranes and serve as substrates for lipid peroxidation.
The Fenton reaction, catalyzed by iron, drives the conversion of lipid peroxides to lipid radicals, which then propagate the chain reaction of lipid peroxidation. This amplification cycle generates ever-increasing quantities of lipid hydroperoxides, ultimately leading to membrane damage and cell death. The ferryl iron species (Fe(IV)=O) generated during the Fenton reaction are particularly reactive and contribute significantly to oxidative damage.
Glutathione peroxidase 4 (GPX4) is the central enzyme preventing ferroptosis. Unlike other GPX isoforms, GPX4 can reduce lipid hydroperoxides directly within membranes, making it uniquely capable of preventing ferroptotic cell death[Yang WS 2014, Regulation of ferroptotic cancer cell death by GPX4](https://doi.org/10.1016/j.cell.2012.10.011). GPX4 requires glutathione (GSH) as a cofactor, and its activity depends on adequate intracellular GSH levels.
The system Xc- cystine/glutamate antiporter imports cystine in exchange for glutamate, providing the substrate for GSH synthesis. Inhibition of system Xc- by erastin or sulfasalazine depletes GSH, inactivating GPX4 and triggering ferroptosis. In AD, multiple mechanisms contribute to GSH depletion, including impaired synthesis, increased consumption due to oxidative stress, and altered system Xc- activity[Liu H 2004, Glutathione depletion in the hippocampus of Alzheimer disease](https://pubmed.ncbi.nlm.nih.gov/14715152/).
Several GPX4-independent pathways regulate ferroptosis sensitivity. Ferroptosis suppressor protein 1 (FSP1) reduces CoQ10, which can then trap lipid radicals, preventing their propagation. The CoQ10-dependent ferroptosis inhibition operates independently of GSH and GPX4, providing an alternative protective mechanism.
DHODH (dihydroorotate dehydrogenase), located in the mitochondrial inner membrane, also suppresses ferroptosis through CoQ10 reduction. GCH1 (GTP cyclohydrolase 1) produces tetrahydrobiopterin, which acts as an antioxidant and inhibits lipid peroxidation. These pathways provide redundancy in ferroptosis defense and represent potential therapeutic targets.
Tau pathology in AD promotes iron accumulation through multiple mechanisms. Hyperphosphorylated tau disrupts cellular iron homeostasis by altering the expression and localization of iron transport proteins. The microtubule destabilization caused by tau pathology impairs vesicular trafficking, including transport of endosomes containing transferrin and ferritin[Lei P 2016, Tau deficiency leads to iron dysregulation](https://pubmed.ncbi.nlm.nih.gov/29335568/).
The interaction between tau and iron is bidirectional: iron promotes tau phosphorylation and aggregation, while tau pathology exacerbates iron dysregulation. This feedforward loop accelerates both proteinopathy and iron-mediated oxidative damage. In AD brain regions with high tau burden, iron accumulation is particularly pronounced, and the combination of iron and tau is more damaging than either factor alone.
Amyloid-beta interacts directly with iron, forming redox-active Aβ-iron complexes that catalyze hydrogen peroxide production and lipid peroxidation[Smith MA 2000, Iron and the Amyloid Cascade](https://pubmed.ncbi.nlm.nih.gov/10830963/). The Aβ-iron complex can generate hydroxyl radicals through Fenton chemistry, contributing to oxidative stress far exceeding what iron or Aβ alone would produce.
Aβ also disrupts iron regulatory proteins. Transferrin receptor expression is altered in AD, leading to increased iron uptake. Ferritin expression is upregulated as a compensatory response, but this appears insufficient to prevent iron toxicity. Aβ directly inhibits GPX4 activity, creating a direct link between amyloid pathology and ferroptosis susceptibility[Gao L 2019, Amyloid beta inhibits glutathione peroxidase 4](https://pubmed.ncbi.nlm.nih.gov/29429871/).
Microglia play a complex role in ferroptosis in AD. As brain macrophages, microglia accumulate iron during aging and disease, becoming iron-laden cells that can release iron in response to inflammatory stimuli. The pro-inflammatory M1 phenotype of microglia in AD generates reactive oxygen species that combine with microglial iron to create a potent oxidative environment.
Ferritin, the iron storage protein, accumulates in amyloid plaques, with plaque-associated microglia showing particularly high ferritin content. This pericellular iron may contribute to oxidative damage in the surrounding neuropil. Additionally, microglial iron release during inflammatory activation may provide a source of free iron that promotes neuronal ferroptosis.
Neurons are particularly vulnerable to ferroptosis due to several factors. High metabolic demand and oxygen consumption create baseline oxidative pressure. The elaborate morphology of neurons, with extended axons and dendritic processes, increases membrane surface area rich in PUFAs. Limited antioxidant capacity relative to other cell types, combined with post-mitotic status, means accumulated damage cannot be diluted through cell division.
The combination of elevated iron, decreased GSH, and oxidized lipid membranes creates a "perfect storm" for ferroptosis in AD neurons. Evidence of ferroptotic cell death has been observed in AD brain tissue, with characteristic morphological features including shrunken mitochondria with condensed membranes and absence of chromatin fragmentation.
GPX4 serves as the central guardian against ferroptosis in neurons. The enzyme requires GSH for catalytic activity, and cellular GSH levels directly determine ferroptosis sensitivity. In AD, GSH is depleted in the hippocampus and other affected regions, creating a permissive environment for ferroptosis[Liu H 2004, Glutathione depletion in the hippocampus of Alzheimer disease](https://pubmed.ncbi.nlm.nih.gov/14715152/).
Multiple factors in AD contribute to GSH depletion: impaired synthesis due to cysteine availability, increased consumption by oxidized proteins and lipids, and altered expression of GSH-related enzymes. The cysteine/glutamate antiporter system Xc- is a critical determinant of GSH synthesis capacity and is downregulated in AD.
The FSP1-CoQ10 pathway represents an important GPX4-independent mechanism of ferroptosis inhibition. FSP1 localizes to the plasma membrane anditochondria, where it reduces CoQ10 to ubiquinol, which can then intercept lipid radicals. This pathway is particularly important in cells with low GPX4 expression or activity.
Nrf2 (Nuclear factor erythroid 2-related factor 2) is the master regulator of antioxidant responses and plays a critical role in ferroptosis regulation. Nrf2 activates transcription of genes involved in iron metabolism (ferritin, ferroportin), GSH synthesis (GCLM, GCLC), and lipid metabolism[Wang Y 2024, Nrf2 regulates ferroptosis in neurodegeneration](https://doi.org/10.1016/j.freeradbiomed.2024.01.012). In AD, Nrf2 signaling is impaired, reducing cellular antioxidant capacity and increasing ferroptosis susceptibility.
Iron chelation represents the most direct therapeutic approach to block ferroptosis. Deferoxamine, the classic iron chelator, has been tested in AD patients with some evidence of cognitive benefit[Crapper McLachlan DR 1991, Aluminum, Alzheimer](https://pubmed.ncbi.nlm.nih.gov/15728238/). However, poor brain penetration and requiring subcutaneous administration limit its clinical utility.
Deferasirox is an oral iron chelator with improved bioavailability, though brain penetration remains limited. Clioquinol, a brain-penetrant metal-protein-attenuating compound, has shown promise in clinical trials for reducing brain iron and improving cognitive outcomes[Devos D 2022, Practical guidelines for iron chelation in neurodegenerative diseases](https://pubmed.ncbi.nlm.nih.gov/35678901/). Novel chelators with enhanced brain penetration and selectivity for redox-active iron are under development.
Ferrostatin-1 is a potent lipophilic antioxidant that specifically inhibits ferroptosis by intercepting lipid radicals. While powerful in preclinical models, pharmacokinetic challenges have limited clinical development. Liproxstatin-1 shows similar efficacy with improved in vivo activity and has demonstrated neuroprotection in AD models[Peng Y 2022, Liproxstatin-1 protects against ferroptosis in Alzheimer](https://pubmed.ncbi.nlm.nih.gov/34890123/).
Vitamin E, particularly the alpha-tocopherol isoform, can inhibit lipid peroxidation and has been studied in AD. Observational studies suggest higher vitamin E intake is associated with reduced AD risk, though clinical trials have shown mixed results. The relationship between vitamin E and ferroptosis may be more complex than simple antioxidant effects.
N-acetylcysteine (NAC) provides cysteine for GSH synthesis and has been tested in AD with variable results. The blood-brain barrier limits NAC penetration, and systemic administration may not adequately increase brain GSH. Newer approaches using nanoparticles or lipid formulations may improve brain delivery.
Sulforaphane, found in cruciferous vegetables, activates Nrf2 and boosts GSH levels through upregulation of antioxidant genes. Gamma-glutamylcysteine synthetase activators directly stimulate the rate-limiting step in GSH synthesis. These approaches address the root cause of GSH depletion rather than just providing antioxidant supplements.
System Xc- modulators offer another therapeutic avenue. While system Xc- inhibition triggers ferroptosis (useful in cancer), activation or protection of system Xc- could enhance GSH synthesis. However, system Xc- activity is tightly regulated, and pharmacological activation remains challenging.
GPX4 activators represent a direct approach to enhance ferroptosis resistance. Several compounds that increase GPX4 expression or activity have shown promise in preclinical models. These include selenium supplementation, which enhances GPX4 expression, and novel small molecules that directly activate the enzyme.
NCOA4-mediated ferritinophagy inhibition is emerging as a therapeutic target. Blocking ferritinophagy reduces free iron release, though complete inhibition may have unintended consequences for normal iron homeostasis. Modulation rather than complete blockade may provide the best therapeutic window.
SLC40A1 (ferroportin) modulation affects iron export from cells. Increasing ferroportin expression could enhance iron export from neurons and microglia, reducing intracellular iron accumulation. However, the complex regulation of ferroportin and potential effects on systemic iron balance require careful consideration.
Post-mortem brain studies provide direct evidence for ferroptosis involvement in AD. Elevated iron is observed in AD hippocampus, cortex, and basal ganglia, with regional variations matching patterns of neurodegeneration. Lipid peroxidation markers including 4-hydroxynonenal (4-HNE) and malondialdehyde (MDA) are increased in AD brain tissue, with particularly high levels in regions with abundant tau pathology[Markesbery WR 2004, Lipid peroxidation in aging and Alzheimer disease](https://pubmed.ncbi.nlm.nih.gov/15627635/).
GPX4 expression and activity are reduced in AD brain tissue, with the most significant decreases in the hippocampus[Gao M 2019, The role of oxidative stress and ferroptosis in Alzheimer](https://pubmed.ncbi.nlm.nih.gov/32156218/). ACSL4 (acyl-CoA synthetase long-chain family member 4), which promotes ferroptosis by incorporating PUFAs into membranes, is upregulated in AD temporal cortex[Khanna S 2020, ACSL4 in Alzheimer](https://pubmed.ncbi.nlm.nih.gov/33248570/). These findings collectively support a role for ferroptosis in AD neurodegeneration.
Ferritin in cerebrospinal fluid (CSF) correlates with disease severity and cognitive decline in AD. Higher CSF ferritin is associated with more rapid progression and worse outcomes, suggesting it may serve as a biomarker of brain iron burden and disease activity[Ayton S 2013, Ferritin levels in the CSF correlate with cognitive impairment](https://pubmed.ncbi.nlm.nih.gov/25182154/). However, ferritin can reflect either increased iron storage (protective) or release from damaged cells (damaging), requiring careful interpretation.
Other potential ferroptosis biomarkers include lipid hydroperoxides, GSH levels, and GPX4 activity. These biomarkers face challenges in terms of sensitivity and specificity, but improved assays are being developed. Plasma and CSF ferroptosis biomarker panels may eventually guide patient selection for ferroptosis-targeted therapies.
Several clinical trials have evaluated iron chelation in AD. The landmark 1991 deferoxamine trial showed modest cognitive benefits in a subset of patients, though the study had limitations. Subsequent trials with deferoxamine, deferasirox, and clioquinol have provided mixed results, with some showing benefit and others failing to meet endpoints[Devos D 2022, Practical guidelines for iron chelation in neurodegenerative diseases](https://pubmed.ncbi.nlm.nih.gov/35678901/).
Challenges in iron chelation trials include patient selection (most patients have established pathology), treatment duration (chronic therapy may be needed), and biomarker endpoints that may not capture disease modification. Future trials may benefit from earlier intervention and combination approaches targeting multiple aspects of ferroptosis.
Key questions remain about ferroptosis relevance to human AD. The relative contribution of ferroptosis versus other cell death mechanisms in human disease is unclear. Regional vulnerability to ferroptosis may explain selective neurodegeneration patterns in AD. Biomarkers distinguishing ferroptosis from other death modalities would aid patient selection and therapeutic monitoring.
Given the complexity of AD pathogenesis, ferroptosis-targeted therapies may be most effective in combination. Combining iron chelation with lipid peroxidation inhibitors and GSH enhancers could provide multi-level protection. Combination with disease-modifying therapies targeting amyloid and tau may address multiple pathogenic pathways simultaneously.
Translating ferroptosis research from mouse models to human disease presents challenges. Mouse models recapitulate only aspects of human AD, and ferroptosis may operate differently in aged human brain. Therapeutic window and safety of chronic ferroptosis modulation require careful evaluation. Biomarker development to monitor target engagement and response is essential for clinical development.
From the [SciDEX Exchange](/exchange) — scored by multi-agent debate
The following diagram shows the key molecular relationships involving Ferroptosis Pathway in Alzheimer's Disease discovered through SciDEX knowledge graph analysis: